code C07AG02PubChem 2585DrugBank APRD00091Chemical dataFormula C24H26N2O4Mol. mass 406.474SMILES eMolecules & PubChemPharmacokinetic dataBioavailability 25–35%Protein binding 98%Metabolism hepatic (CYP2D6, CYP2C9)Half life 7–10 hoursExcretion renal 16%, faecal coreg dosage considerationsPregnancy cat. C(AU).

non-selective beta blocker indicated in the US as Coreg CR (GSK).Contents [hide]1 Pharmacology2 Clinical use2.1 U.S. supply issues2.2 Approval of controlled-release formulationOn coreg dosage 20, 2006, the FDA approved a controlled release formulation of carvedilol, to be marketed as Coreg CR (GSK).Contents [hide]1 Pharmacology2 Clinical use2.1 U.S. supply issues2.2 Approval of coreg dosage formulationOn October 20, coreg dosage the FDA approved a controlled release formulation of carvedilol, to be marketed as Coreg CR (GSK).Contents [hide]1 Pharmacology2 Clinical coreg dosage U.S. supply issuesOn January 10, 2006 carvedilol coreg dosage became limited in the United States, due to changes in documentation procedures at a plant. This coreg dosage lifted in April 27, 2006 in a Dear coreg dosage letter. [1][edit] Approval of controlled-release formulationOn October 20, 2006, the FDA approved a controlled release formulation of carvedilol, to be marketed as Coreg CR coreg dosage [hide]1 Pharmacology2 Clinical use2.1 U.S. supply.

Carvedilol improves survival in severe chronic heart failure. However, to date this theoretical benefit has not been coreg dosage in clinical.